Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 4 4Phase 3 4Phase 2 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Adrenocortical Hyperfunction 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Interventional × Cabergoline × Clear all
NCT05981742 2023-08-08

Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS

Al-Rasheed University College

Phase 2 Completed
75 enrolled

Polycystic Ovary Syndrome

NCT01915303 2020-09-18

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Novartis

Phase 2 Terminated
68 enrolled 25 charts
Endocrine

Adrenocortical Hyperfunction, Pituitary Neoplasms, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡